Open Access
ARTICLE
Fangjin Lu*, Bin Mu†, Ge Jin*, Lin Zhu‡, Ping Mu§
Oncology Research, Vol.29, No.1, pp. 1-10, 2021, DOI:10.3727/096504021X16401852341873
Abstract NeuroD1 is a neuronal differentiation factor that contains a basic helix–loop–helix (bHLH) motif. Recently,
NeuroD1 was found to be associated with tumorigenesis in neuroblastoma (NB) and is known to promote cell
proliferation and migration in these cells. Here we found that MYCN regulates the expression of NeuroD1 in
NB cells and that the downregulation of MYCN using short hairpin RNAs (shRNA) results in the inhibition
of cellular proliferation in NB cells. Moreover, the phenotype induced by MYCN shRNA was rescued by
the exogenous expression of NeuroD1. Chromatin immunoprecipitation (ChIP) assay showed that MYCN
directly binds to the E-box element in… More >
Open Access
ARTICLE
Kazuhiro Yamamoto*, Takeshi Ioroi*, Kazuaki Shinomiya†, Ayaka Yoshida*, Kenichi Harada‡, Masato Fujisawa‡, Tomohiro Omura*, Yasuaki Ikemi§, Shunsaku Nakagawa§, Atsushi Yonezawa§, Osamu Ogawa¶, Kazuo Matsubara§, Takuya Iwamoto#, Kohei Nishikawa**, Sayaka Hayashi††,
Daichi Tohara††, Yoji Murakami‡‡, Takanobu Motoshima‡‡, Hirofumi Jono††, Ikuko Yano*§
Oncology Research, Vol.29, No.1, pp. 11-23, 2021, DOI:10.3727/096504022X16418911579334
Abstract We evaluated the association of signal transducer and activator of transcription 3 (STAT3) polymorphisms with
the incidence of mammalian target of rapamycin (mTOR) inhibitor-induced interstitial lung disease (ILD) in
patients with renal cell carcinoma (RCC). We also used lung-derived cell lines to investigate the mechanisms
of this association. Japanese patients with metastatic RCC who were treated with mTOR inhibitors were genotyped for the STAT3 polymorphism, rs4796793 (−1697C/G). We evaluated the association of the STAT3 genotype with the incidence of ILD and therapeutic outcome. In the 57 patients included in the primary analysis, the
ILD rate within 140 days was significantly… More >
Open Access
ARTICLE
Shuai Liu*†1, Lu Lu*†1, Feng Pan‡, Chunsheng Yang*†, Jing Liang§, Jinfeng Liu¶, Jian Wang#, Rong Shen**, Fu-Ze Xin††, Nan Zhang*†
Oncology Research, Vol.29, No.1, pp. 25-31, 2021, DOI:10.3727/096504022X16427607626672
Abstract Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd.,
Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients.
We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different
institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free
survival (PFS) was evaluated using the… More >
Open Access
ARTICLE
Angela Silvano*†1, Giulio Menegazzi*1, Silvia Peppicelli*1,
Caterina Mancini*, Alessio Biagioni*, Alessandro Tubita*, Ignazia Tusa*, Jessica Ruzzolini*, Matteo Lulli*, Elisabetta Rovida*, Persio Dello Sbarba*
Oncology Research, Vol.29, No.1, pp. 33-46, 2021, DOI:10.3727/096504022X16442289212164
Abstract This study was directed to deepen the effects of nutrient shortage on BCR/Ablprotein expression and signaling in
chronic myeloid leukemia (CML) cells. The backbone of the study was cell culture in medium lacking glucose,
the consumption of which we had previously shown to drive BCR/Ablprotein suppression, and glutamine, the
other main nutrient besides glucose. In this context, we focused on the role of lactate, the main by-product of
glucose metabolism under conditions of rapid cell growth, in particular as a modulator of the maintenance of
CML stem/progenitor cell potential, a crucial determinant of disease course and relapse of disease. The… More >
Open Access
ARTICLE
Hsiang-Lin Tsai*†, Yen-Cheng Chen*‡, Tzu-Chieh Yin*§¶, Wei-Chih Su*‡, Po-Jung Chen*,Tsung-Kun Chang*†, Ching-Chun Li*, Ching-Wen Huang*†, Jaw-Yuan Wang*†‡#**††‡‡
Oncology Research, Vol.29, No.1, pp. 47-61, 2021, DOI:10.3727/096504022X16451187313084
Abstract Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased
susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type metastatic colorectal cancer (mCRC) patients treated
with cetuximab or bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation as the
first-line therapy. In total, 173 patients with mCRC with RAS wild-type were enrolled. Among them, 98 patients
were treated with cetuximab, whereas 75 patients were treated with bevacizumab. All patients received irinotecan dose escalation based on UGT1A1 genotyping. We compared the progression-free survival (PFS),… More >
Open Access
REVIEW
Yudie Yang*1, Xia Zhang†1, Yajie Gao*, Yan Dong*, Di Wang*, Yanping Huang*, Tianhao Qu*, Buqun Fan*, Qizheng Li*, Chunxia Zhang*, Xiaonan Cui*, Bin Zhang*
Oncology Research, Vol.29, No.1, pp. 63-74, 2021, DOI:10.3727/096504022X16462176651719
Abstract Lung cancer is a malignant tumor with high incidence and mortality across the world. The use of immune
checkpoint inhibitors for lung cancer has improved the prognosis of some lung cancer patients to a greater
extent and provided a new direction for the clinical treatment of lung cancer. Immunotherapy still has limitations in terms of its appropriate population and adverse reactions. Particularly for non-small cell lung cancer
(NSCLC) patients with epidermal growth factor receptor (EGFR) mutation, there has been no major breakthrough in current immunotherapy. Whether immunotherapy can bring new benefits after drug resistance is
induced by tyrosine kinase inhibitor-targeted… More >
Open Access
RETRACTION
Hai-Feng Zeng*, Hai-Yan Qiu†, Fa-Bo Feng*
Oncology Research, Vol.29, No.1, pp. 75-75, 2021, DOI:10.3727/096504022X16420719767471
Abstract This article has no abstract. More >
Open Access
RETRACTION
Jianping Xu, Liguo Sun, Wei Sun, Jianhai Tian, Huaiyuan Guo
Oncology Research, Vol.29, No.1, pp. 77-77, 2021, DOI:10.3727/096504022X16425915715943
Abstract This article has no abstract. More >
Open Access
RETRACTION
Jianjun Shen*, Weina Niu†, Hongbo Zhang*, Ma Jun*, Hongyan Zhang*
Oncology Research, Vol.29, No.1, pp. 79-79, 2021, DOI:10.3727/096504022X16491544361323
Abstract This article has no abstract. More >
Login
Register
Submit a Paper
Propose a Special lssue